What question did this study set out to answer?

To investigate the role of NECTIN4 amplification as a biomarker in metastatic urothelial carcinoma.

April 10, 2026Open Access

NECTIN4 amplification is a frequent event in central nervous system metastases of urothelial carcinoma

Puntos clave

To investigate the role of NECTIN4 amplification as a biomarker in metastatic urothelial carcinoma.
Analysis of NECTIN4 amplification in central nervous system metastases.
Evaluation of its predictive value for targeted anti-NECTIN4 therapies.
Comparison with other cancers like triple-negative breast cancer and non-small cell lung cancer.
NECTIN4 amplification was frequently observed in CNS metastases of urothelial carcinoma.
Identification of NECTIN4 as a potential predictor of therapy response.
Amplification presence suggests therapeutic targeting possibilities.

Resumen

Introduction & objectives:NECTIN4 amplification has emerged as a promising biomarker for predicting response to targeted anti-NECTIN4 therapies in metastatic urothelial carcinoma (mUC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). The anti-NECTIN4 antibody-drug for full text, please go to the a.m. URL

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo